Tempest Therapeutics (TPST) said Thursday it is working with Roche to advance amezalpat into a phase 3 trial in combination with atezolizumab and bavacizumab for the first-line treatment of unresectable or metastatic hepatocellular carcinoma.
As part of the agreement, Roche will provide atezolizumab worldwide, while Tempest will sponsor and lead the trial, Tempest said, adding that it retains full commercial and development rights to amezalpat.
Tempest shares were up more than 27% in recent premarket activity Thursday.
Price: 1.7200, Change: +0.37, Percent Change: +27.41
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments